The extensive lawsuit against drugmakers Novo Nordisk and Eli Lilly concerning their GLP-1 class medications, which include Ozempic, Wegovy, Mounjaro, Trulicity, and Zepbound, is moving forward under the oversight of a new judge, Karen Marston. These drugs are widely prescribed for diabetes and obesity management.


The lawsuit claims that the pharmaceutical companies failed to adequately warn users about severe and potentially life-threatening digestive side effects, such as gastroparesis, severe vomiting, and gallbladder issues. The case has gained momentum following the passing of the previous judge, with Judge Marston now taking the helm.


Currently, lawyers from both sides are working on finalizing a detailed plaintiff fact sheet. This document will include information on individual injuries, medical history, and other pertinent details. Defense attorneys view the fact sheet as a tool to identify and dismiss frivolous claims, while plaintiffs' lawyers argue that it should not be used for this purpose and that further discovery is essential. Given the complexity and scale of the case, it is anticipated to be lengthy, with extensive discovery and potentially bellwether trials to gauge the direction of the overall litigation.

Have You Suffered Due to Negligence at an Event? Contact Indianapolis’ Trusted Personal Injury Attorneys

We are easy to talk to and here to help. Don't let important evidence get lost—protect your rights now. Contact us for a free consultation and let our experienced injury lawyers guide you through this difficult time.